ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6085
-0.43%
Brent Oil
83.76
0.67%
Bitcoin
66,814.32
2.41%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Apellis Pharmaceuticals Inc (APLS)

  7. Apellis Pharmaceuticals Inc (APLS) Noticias

APLS

Apellis Pharmaceuticals (APLS)

Apellis Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:APLS
FechaHoraFuenteTítuloSímboloCompañía
14/05/202407:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APLSApellis Pharmaceuticals Inc
14/05/202407:00GlobeNewswire Inc.Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth StreetNASDAQ:APLSApellis Pharmaceuticals Inc
09/05/202416:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
08/05/202416:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
07/05/202406:05GlobeNewswire Inc.Apellis Pharmaceuticals Reports First Quarter 2024 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
07/05/202406:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:APLSApellis Pharmaceuticals Inc
06/05/202406:00GlobeNewswire Inc.Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
01/05/202406:00GlobeNewswire Inc.Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingNASDAQ:APLSApellis Pharmaceuticals Inc
26/04/202406:15GlobeNewswire Inc.Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)NASDAQ:APLSApellis Pharmaceuticals Inc
23/04/202406:00GlobeNewswire Inc.Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
04/04/202415:05GlobeNewswire Inc.Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:APLSApellis Pharmaceuticals Inc
01/04/202406:00GlobeNewswire Inc.Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
11/03/202406:00GlobeNewswire Inc.Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina AdvisorNASDAQ:APLSApellis Pharmaceuticals Inc
29/02/202416:10Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:APLSApellis Pharmaceuticals Inc
27/02/202406:35Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:APLSApellis Pharmaceuticals Inc
27/02/202406:05GlobeNewswire Inc.Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
27/02/202406:01Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:APLSApellis Pharmaceuticals Inc
26/02/202406:00GlobeNewswire Inc.Apellis Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:APLSApellis Pharmaceuticals Inc
20/02/202406:00GlobeNewswire Inc.Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
14/02/202416:18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:APLSApellis Pharmaceuticals Inc
14/02/202409:04Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:APLSApellis Pharmaceuticals Inc
26/01/202406:06GlobeNewswire Inc.Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of ApplicationNASDAQ:APLSApellis Pharmaceuticals Inc
08/01/202408:00GlobeNewswire Inc.Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product RevenuesNASDAQ:APLSApellis Pharmaceuticals Inc
02/01/202406:00GlobeNewswire Inc.Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
28/12/202306:00GlobeNewswire Inc.Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
14/12/202306:00GlobeNewswire Inc.Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European UnionNASDAQ:APLSApellis Pharmaceuticals Inc
11/12/202306:00GlobeNewswire Inc.EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual MeetingNASDAQ:APLSApellis Pharmaceuticals Inc
21/11/202306:00GlobeNewswire Inc.Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
04/11/202312:37GlobeNewswire Inc.SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)NASDAQ:APLSApellis Pharmaceuticals Inc
01/11/202306:51Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:APLSApellis Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:APLS

Su Consulta Reciente

BIT
UC2X0T
Unicredit Bank
NASDAQ
LMDX
LumiraDx
LSE
KRW
Am Korea Etf
BITMOT
820157
Dbahnfinance Tf 1,5% Dc3...
EU
1184T
1184T
LSE
0JXQ
Main Street Capital
EU
ISTSL
LS STSL INAV
ASX
EVODB
Embark Education
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados